Form4insider filings, from the source

SEC Form 3 · accession 0001209191-19-003288

UroGen Pharma Ltd. · URGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Ran Nussbaum
Director
Period of report
Jan 1, 2019
Accepted (ET)
Jan 10, 2019 · 5:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001668243

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Ordinary SharesF1holding———968,525ISee Footnote
Ordinary SharesF2holding———452,162ISee Footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F1,F3$5.00holding————Jul 27, 2021Ordinary Shares2,211—I
Stock Option (right to buy)F1,F3$5.00holding————Sep 1, 2022Ordinary Shares2,211—I
Stock Option (right to buy)F1,F4$5.94holding————Dec 27, 2022Ordinary Shares32,723—I
Stock Option (right to buy)F1,F5$59.23holding————Jun 4, 2028Ordinary Shares6,817—I
Stock Option (right to buy)F2,F3$5.00holding————Jul 27, 2021Ordinary Shares1,030—I
Stock Option (right to buy)F2,F3$5.00holding————Sep 1, 2022Ordinary Shares1,030—I
Stock Option (right to buy)F2,F4$5.94holding————Dec 27, 2022Ordinary Shares15,276—I
Stock Option (right to buy)F2,F5$59.23holding————Jun 4, 2028Ordinary Shares3,183—I

Explanation of responses

Remarks

Exhibit List - Exhibit 24 - Power of Attorney